Cemiplimab - Regeneron Pharmaceuticals

Drug Profile

Cemiplimab - Regeneron Pharmaceuticals

Alternative Names: REGN-2810; SAR-439684

Latest Information Update: 13 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Regeneron Pharmaceuticals
  • Developer Inovio Pharmaceuticals; Regeneron Pharmaceuticals; Sanofi
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Programmed cell death-1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Squamous cell cancer
  • Phase III Cervical cancer; Non-small cell lung cancer
  • Phase II Basal cell cancer
  • Phase I/II Glioblastoma; Multiple myeloma; Prostate cancer
  • Phase I B cell lymphoma; Cancer; Head and neck cancer; Lymphoma; Malignant melanoma

Most Recent Events

  • 10 Apr 2018 Regeneron Pharmaceuticals in collaboration with Sanofi initiates an expanded-access programme for Squamous Cell Cancer in April 2018 (NCT03492489)
  • 04 Apr 2018 Sidney Kimmel Cancer Center and Regeneron Pharmaceuticals plans a phase I trial for Prostate Cancer (Late stage disease, Metastatic disease, Neoadjuvant therapy, Monotherapy, Combination therapy) in USA, in December 2018 (NCT03477864)
  • 03 Apr 2018 Preregistration for Squamous cell cancer (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Monotherapy) in European Union (IV) before April 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top